COMMUNIQUÉS West-GlobeNewswire

Aleafia Labs Partners on Cannabinoid Pharmacogenetics Study
30/10/2018
Study with G420, US-Based AKESOgen aimed at producing genetic tools for improved medical cannabis therapy TORONTO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Aleafia Labs, a division of Aleafia Health Inc. (TSXV: ALEF: OTCQX: [...]
NeoGenomics Reports 17% Revenue Growth to Record $69 Million
30/10/2018
FT. MYERS, Fla., Oct. 30, 2018 (GLOBE NEWSWIRE) -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the third quarter of 2018. Third Quarter [...]
Antares Pharma to Report Third Quarter 2018 Financial and Operating Results
30/10/2018
EWING, N.J., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2018 financial results and recent operating progress before the market opens on [...]
EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors
30/10/2018
- Seasoned Pharmaceutical R&D and Operations Leader with over 30 Years of Experience - WATERTOWN, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical [...]
Maple Leaf Enters into a Supply Agreement with Cannmart Inc.
30/10/2018
CALGARY, Alberta, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Maple Leaf Green World Inc. (“ Maple Leaf ” or the “ Company ”) ( NEO: MGW, OTCQX: MGWFF ) announces that the Company has entered into a product acquisition agreement [...]
TRU NIAGEN® Recognized as Best Product & Most Popular Brand at Health, Wellness & Beauty Awards 2018 of Watsons Hong Kong
30/10/2018
TRU NIAGEN ® (nicotinamide riboside) receives best product award and recognized as top seller in 2018 amongst Watsons Hong Kong members LOS ANGELES, Oct. 30, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) [...]
Correction to third quarter 2018 financial statements
30/10/2018
Company announcement no. 8-2018 Birkerød, 30 October 2018 ViroGates A/S (Nasdaq First North Denmark: VIRO), announced its financial results for the third quarter 2018 (1 July – 30 September) on 24 October 2018. Certain [...]
Transactions in relation to share buyback program
30/10/2018
Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
CorVel Announces Revenues and Earnings
30/10/2018
IRVINE, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) announced the results for the quarter ended September 30, 2018. Revenues for the quarter ended September 30, 2018 were $148 million, an [...]
G1 Therapeutics to Provide Third Quarter 2018 Corporate and Financial Update on November 7, 2018
30/10/2018
RESEARCH TRIANGLE PARK, N.C., Oct. 30, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a [...]
Orion Corporation: Managers' transactions - Konsta Westerlund
30/10/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 30 OCTOBER 2018 at 10.45 EET Orion Corporation: Managers' transactions - Konsta Westerlund Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]
Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update
30/10/2018
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]
Clementia Announces Pricing of Public Offering of Common Shares
30/10/2018
MONTREAL, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, [...]
Clementia annonce le prix de son émission publique d’actions ordinaires
30/10/2018
MONTRÉAL, 29 oct. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ : CMTA), une société biopharmaceutique au stade clinique proposant des traitements novateurs pour les personnes atteintes de troubles [...]
Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Precision Therapeutics Inc.: SEC File Nos. 001-36790; and 333-221966
30/10/2018
Precision Therapeutics Files Form S-4 Regarding Proposed Merger with Helomics Holding Corporation MINNEAPOLIS, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company [...]
REVA to Hold Third Quarter 2018 Financial Results Call
30/10/2018
SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its third quarter 2018 financial results and provide a business update. The [...]
CTD Holdings Announces Filing of Patent Application for Use of Hydroxypropyl Beta Cyclodextrins in the Treatment of Alzheimer’s Disease
29/10/2018
ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, [...]
Hemispherx’s Presentation at the Dawson James Securities 4th Annual Small Cap Growth Conference to Be Livestreamed
29/10/2018
OCALA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company focused on unmet medical needs in immunology, will [...]
Amedisys Reports Third Quarter 2018 Financial Results and Updates 2018 Guidance
29/10/2018
BATON ROUGE, La., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month period ended September 30, 2018. Three Month Periods Ended September 30 [...]

Pages